Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy

This publication has 64 references indexed in Scilit:

• “Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
  Molecular Cancer Research, 2006
• VEGF as a Therapeutic Target in Cancer
  Oncology, 2005
• Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
  Molecular Cancer Therapeutics, 2005
• Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines
  Radiotherapy and Oncology, 2005
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
  Science, 2005
• Treatment of HER-2/ neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
  Clinical Cancer Research, 2004
• Incipient Angiogenesis
  JNCI Journal of the National Cancer Institute, 2000
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
  Nature, 1992
• Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia
  Biochemical and Biophysical Research Communications, 1990